Oncternal Therapeutics’ (ONCT) Hold Rating Reaffirmed at Brookline Capital Management

Brookline Capital Management reiterated their hold rating on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Thursday, Marketbeat reports.

A number of other research firms also recently commented on ONCT. HC Wainwright dropped their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a report on Monday, August 12th. StockNews.com initiated coverage on Oncternal Therapeutics in a report on Sunday, September 8th. They set a hold rating for the company. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Hold and a consensus target price of $20.00.

Oncternal Therapeutics Price Performance

NASDAQ:ONCT opened at $1.46 on Thursday. The firm has a market cap of $4.32 million, a PE ratio of -0.12 and a beta of 1.39. The firm has a 50 day simple moving average of $5.37 and a 200-day simple moving average of $7.45. Oncternal Therapeutics has a 1-year low of $1.32 and a 1-year high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. During the same quarter in the prior year, the company posted ($3.00) EPS. As a group, sell-side analysts expect that Oncternal Therapeutics will post -11.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.